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Abstract
Background: To investigate the association of the change of painful physical symptoms (PPS) after 4 weeks, with
the 6-month treatment outcomes of depressive symptoms in patients treated with duloxetine in clinical practice.
Methods: Multicenter, prospective, 6-month, non-interventional study in adult outpatients with a depressive
episode and starting treatment with duloxetine. Depression severity was assessed by the clinician (Inventory for
Depressive Symptomatology [IDS-C]) and patient (Kurz-Skala Stimmung/Aktivierung [KUSTA]). Somatic symptoms
and PPS were assessed using the patient-rated Somatic Symptom Inventory (SSI) and visual analog scales (VAS) for
pain items. Association of change in PPS with outcomes of depressive symptoms was analyzed based on mean
KUSTA scores (mean of items mood, activity, tension/relaxation, sleep) and achievement of a 50% reduction in the
total IDS-C score after 6 months using linear and logistic regression models, respectively.
Results: Of the 4,517 patients enrolled (mean age: 52.2 years, 71.8% female), 3,320 patients (73.5%) completed the
study. 80% of the patients had moderate to severe overall pain (VAS > 30 mm) at baseline. A 50% VAS overall pain
reduction after 4 weeks was associated with a 13.32 points higher mean KUSTA score after 6 months, and a 50%
pain reduction after 2 weeks with a 6.33 points improvement. No unexpected safety signals were detected in this
naturalistic study.
Conclusion: Pain reduction after 2 and 4 weeks can be used to estimate outcomes of long-term treatment with
duloxetine. PPS associated with depression have a potential role in predicting remission of depressive symptoms in
clinical practice.
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Background
Depressive patients frequently report somatic symptoms
including painful physical symptoms (PPS) accompany-
ing their depression (mean prevalence 65%) [1]. The
causal relationship between pain and depression remains
unclear [2-4]. Pain can be a symptom, a cause, or a con-
sequence of depression [2]. Neurobiological evidence
suggests that mood and chronic pain are connected via
the serotonin and noradrenalin neurotransmitter
pathways. A malfunctioning of the descending seroto-
nergic and noradrenergic pathways could allow routine
sensory input to be interpreted as uncomfortable or
even painful [5,6]. Studies investigating the direction of
the association between pain and depression suggest
that it is the stress of living with chronic pain that
causes depression [7], but there is also evidence that
pain develops secondary to depression through increases
in pain sensitivity and that high depression scores result
in a greater risk of developing chronic pain [8].
In 69% of depressed patients, painful or non-painful
physical symptoms were the only presenting complaints
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ness of depression, missed diagnosis [10,11] and inap-
propriate treatment [12]. Conversely, failure to treat PPS
in depressed patients may adversely impact depression
treatment outcomes [13,14]. Recognizing and optimizing
the management of pain that commonly coexists with
depression may be important in enhancing depression
response and remission rates [15]. The presence of
severe pain at start of depression treatment has been
associated with non-response to antidepressants [16],
and a lower overall pain severity score at baseline was
associated with higher odds of achieving remission [17].
In a naturalistic clinical trial addressing long-term
treatment of PPS and emotional depressive symptoms
[ 1 8 ] ,i tw a sf o u n dt h a tt h ee f f e c to fs e l e c t i v es e r o t o n i n
reuptake inhibitors (SSRIs) on PPS was less pronounced
than on the emotional symptoms. However, this trial
was restricted to SSRIs, and it is argued that for an ade-
quate pain response, substances affecting both serotonin
and noradrenaline are necessary [19].
Extensive data support the efficacy of tricyclic antide-
pressants (TCAs) for the alleviation of pain in chronic
pain patients [20], and also the newer serotonin and nor-
adrenaline reuptake inhibitors (SNRIs) duloxetine [14],
venlafaxine [21] and milnacipran [22] have shown effi-
cacy in the treatment of pain and depression. Duloxetine
is a SNRI with proven efficacy for PPS of depression
[14,23,24]. Analyses from short-term trials demonstrated
that a greater reduction in pain was associated with a
higher probability of remission [14,25]. Furthermore, the
efficacy of duloxetine has been also proven for the treat-
ment of painful diabetic neuropathy [26].
The primary research objective of the present 6-
month, observational study with duloxetine (’PADRE’)
was to investigate the association of an early improve-
ment in PPS with long-term changes in depressive
symptoms, which could be used as a predictor of long-
term treatment outcomes in depression. Such a predic-
tor could be helpful for an early adjustment of treat-
ment to the individual patient [27].
Methods
Study Design
The present multicenter, prospective, non-interventional
study (F1J-SB-B009) investigated the influence of early
changes in PPS in depressed patients on long-term
changes in depressive symptoms during treatment with
duloxetine in clinical practice over a period of 6 months.
The study was conducted at 693 centers in Germany.
Initially, all psychiatrists/neurologists of the Lilly data-
base (about 5000, representing about 70% of office
based psychiatrists/neurologists who are involved in
pharmacological treatment of depression in Germany)
were contacted and finally 693 centers actively
participated in the study. Outpatients (age ≥ 18 years)
with a depressive episode (according to ICD-10) who
were initiated to antidepressive treatment with duloxe-
tine were allowed to enter the study. Treatment patterns
were solely at the discretion of the physician and the
patient.
The study was approved by the appropriate ethics
committee and notified to the German national author-
ity (BfArM, Bundesinstitut für Arzneimittel und Medi-
zinprodukte). Patients provided written consent to the
collection and release of anonymized data (according to
the Declaration of Helsinki).
Data were collected at baseline (i.e. prescription of
duloxetine), after 2 weeks, 1, 3, and 6 months, or at
early discontinuation of observation. The study was con-
ducted from August 2005 until December 2007.
Assessments
Depressive symptoms were assessed using the daily self-
rating KUSTA scale (Kurz-Skala Stimmung/Aktivierung
- Short Mood/Drive Scale) [28]. A high criteria-related
validity is indicated by correlations with other rating
scales such as the Hamilton Rating Scale for Depression
(HAMD; maximum correlation coefficient: r = 0.93). For
the present study, the KUSTA items mood, activity, ten-
sion/relaxation and sleep were each rated on a 100 mm
Visual Analogue Scale (VAS), and a “mean KUSTA
score” determined by calculating the arithmetic mean
from the values of these 4 items.
The Inventory for Depressive Symptomatology (IDS)
[29] is an instrument for the evaluation of the severity
of depression. A validated German translation of the
clinician rated version (IDS-C) with 30 items was used
[30]. The items address simple, single symptoms rated
on a 4-step Likert scale ranging from 0 to 3, with sever-
ity levels described in terms relevant to each item.
Changes in PPS were assessed by using self-rated VAS
for overall pain, headache, shoulder/neck pain, back
pain, joint pain, thoracic pain, and abdominal pain.
Changes in painful and non-painful physical symp-
toms were assessed by the patient-rated Somatic Symp-
tom Inventory (SSI) [31]. The SSI consists of 28
symptoms, each of which is rated on a 5-point Likert
scale (1 = “not at all” to 5 = “very much”).
The outcome assessments were conducted at the visits
in the physician’s office, either by the patient (KUSTA,
VAS pain, SSI) or by the investigator (IDS-C).
Improvements are indicated by a decrease of the
respective scores for IDS-C, VAS Pain and SSI, and by
an increase of the Mean KUSTA score.
Demographics and other baseline parameters, treat-
ment decisions, concomitant use of analgesics, hospitali-
zations for depression, and tolerability data (adverse
events [AEs]) were collected.
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For this study, about 4,300 patients were planned to be
recruited. This sample size allows measurement of
changes in pain using the VAS with adequate precision
(10% of the standard deviation [SD]) in all subgroups
derived from the combination of gender and baseline
pain (≤ 30 or > 30 mm VAS [32]). It was assumed that
the smallest subgroup, comprising one ninth of the
population, would be males with baseline pain > 30
mm, and that 20% of the patients would not provide fol-
low-up data.
Data analyses were performed using SAS version 9.1.3
statistical software. All analyses were exploratory; no
confirmatory statistical tests were performed, or state-
ments derived. Continuous variables were summarized
using descriptive statistics (number of patients, mean,
median, SD, range) and binary or categorical variables
using absolute and relative frequencies. A conservative
test of whether mean changes over time were statisti-
cally significant was done by seeing whether the 95%
confidence intervals for the means at the time points
overlapped. To address the primary objective, the Mean
KUSTA score and whether or not patients had achieved
a ≥ 50% reduction in the total IDS-C score at the final
visit were analyzed, using linear and logistic regression
models, respectively. These models included the follow-
ing variables:
￿ Baseline score of the outcome variable
￿ Gender, age, employment status, whether living
alone
￿ Number of weeks unable to work in the last 12
months
￿ Currently unable to work
￿ Duration of depression
￿ Concomitant psychiatric/somatic diseases
￿ Baseline psychotropic/permanent pain medication
￿ Pain symptoms at baseline
￿ Initial dose of duloxetine
￿ Overall pain VAS at baseline
￿ ≥ 50% overall pain VAS reduction at 4 weeks
￿ ≥ 50% reduction in SSI painful symptoms subscore
at 4 weeks
￿ SSI painful and non-painful symptom subscores at
baseline
All of these independent variables were included in a
full model and then removed stepwise. Model calcula-
tion was repeated with 50% reduction in VAS for overall
pain and SSI between baseline and 2 weeks instead of at
4 weeks. Post-hoc, this model was repeated for patients
with clinically relevant (> 30 mm) baseline pain only.
The effect of non-painful physical symptoms on out-
comes was also investigated using regression methods.
Model fit was checked by reviewing plots of residuals
for the linear regression and the Hosmer-Lemeshow
goodness-of-fit test for logistic models. Sensitivity ana-
lyses (last observation carried forward [LOCF], repeated
measures) were performed to check the robustness of
the primary analysis.
A further post-hoc analysis in patients with > 30 mm
pain at baseline examined the predictive value of an
early response in depressive symptoms (using the IDS-C
score, ≥ 50% reduction after 4 weeks and ≥ 20% reduc-
tion after 2 weeks) in conjunction with an early
response in pain (≥ 5 0 %r e d u c t i o ni no v e r a l lp a i nV A S
after 4 weeks and ≥ 20% reduction after 2 weeks) and
other possible predictive factors.
Data quality was assured by implementing a data vali-
dation plan and double data entry. Data from incom-
plete scales (i.e. missing values for one or more items)
were excluded from statistical analysis for the respective
visit and patient.
Results
Patients
A total number of 4,517 patients were enrolled into the
study, 3,320 patients (73.5%) reached the endpoint at
Visit 5 (6-month [see Figure 1]). Reasons for disconti-
nuation could be documented from 514 patients (321
b e f o r eV i s i t5a n d1 9 3a tV i s i t5 ) .T h em o s tf r e q u e n t l y
reported reasons for discontinuation were patient deci-
sion (34.0%, 175 of 514 patients) and AE (23.2%, 119 of
514 patients). Patients’ demographics, diagnoses, and
medical history are summarized in Table 1.
Medication
At study entry, 45.8% of the patients started duloxetine
treatment as their initial medication for depression,
50.3% were switched due to inadequate effectiveness of
their previous medication. The remainder named differ-
ent reasons for their switching to duloxetine. The initial
duloxetine dose was 30 mg/d in 72.9% of the patients.
At 2 and 4 weeks, 64.8% and 73.0% of the patients
received 60 mg/d respectively.
Efficacy Results
Depressive Symptoms
The mean KUSTA score continuously increased over time
(p < 0.05). Correspondingly, the IDS-C total score con-
tinuously decreased over time (p < 0.05). The development
over time of all individual KUSTA items was similar to
that of the mean KUSTA score. Details on the mean
KUSTA score and IDS C score are given in Table 2.
Painful and Non-painful Physical Symptoms
VAS pain scores and SSI scores improved continuously
over time during the study (p < 0.05) as shown in
Table 2.
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with a reduction of ≥ 30% or ≥ 50% in VAS overall pain
from baseline to 6 months are shown in Table 2. There
was a consistent decrease in the number of patients
with a VAS overall pain score of > 30 mm during the
course of the study, from 80.0% at baseline to 43.9% at
Month 6.
Primary Analysis
The linear regression analysis showed that in the applied
model, a 50% reduction in overall pain VAS during the
first 4 weeks had the strongest association (F-value =
158.6; p < 0.0001) of all variables assessed with the
mean KUSTA score at 6 months. For patients with a ≥
50% reduction in overall pain VAS during the first 4
w e e k s ,t h em e a nK U S T As c o r ea t6m o n t h sw a se s t i -
mated to be 13.32 points higher than for patients with-
out a ≥ 50% reduction. These results were supported by
sensitivity analyses based on LOCF and repeated mea-
sures approaches. The results were similar for patients
with baseline pain > 30 mm. All variables with a statisti-
cally significant effect in the regression analysis of the
mean KUSTA score are given in Table 3.
In the logistic regression analysis of the response rate
in the IDS-C total score (50% reduction [yes/no]), the
I D S - Ct o t a ls c o r ea tb a s e l i n ea n dt h ec h a n g ei nt h e
overall pain VAS during the first 4 weeks had the stron-
gest effect (p < 0.0001) among the factors included in
the model.
The odds ratio for the change in the overall pain
VAS during the first 4 weeks was 3.00 (95% CI: 2.41-
3.75). This indicates that for patients with a ≥ 50%
reduction in their overall pain VAS during the first 4
weeks, the odds of achieving a 50% reduction in the
IDS-C total score after 6 months is 3 times higher
than for those who did not. Expressed as relative risks,
the probability of achieving a 50% reduction in the
IDS-C total score was 1.45 times higher for those
patients with an early ≥ 50% reduction in their overall
pain VAS.
Further statistically significant factors were similar to
those seen in the analysis of the mean KUSTA score.
When performing the model based on 2-week data,
the ≥ 50% reduction in overall pain VAS during the first
2 weeks was identified as a relevant factor in influencing
the outcome of depressive symptoms after 6 months.
Two-week data were associated with a 6.33 point
improvement in the 6-month mean KUSTA score, com-
pared with patients without a ≥ 50% pain reduction.
Discontinued duloxetine at Visit 3: N=83
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Discontinued duloxetine at Visit 2: N=135
No Visit 2 Information: N=275
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Visit 5 (6 months)
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N=3,320
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Figure 1 Patient Flow Chart.
Schneider et al. BMC Psychiatry 2011, 11:150
http://www.biomedcentral.com/1471-244X/11/150
Page 4 of 10The remission rate based on IDS-C (total score ≤ 12)
after 6 months was 45.9% for all patients. In a regression
analysis, pain reduction (decrease in VAS overall pain of
≥ 50%) during the first 4 weeks was the factor most
strongly associated with remission rate (p < 0.0001),
with an odds ratio of 2.90 (95% CI: 2.38-3.52). The rela-
tionship between an early pain reduction after 2 and 4
weeks and the remission rate after 6 months is shown
in Figure 2. The remission rate in patients with an early
pain reduction after 2 weeks (62.8%) was almost as high
as in patients with a pain reduction after 4 weeks
(66.9%).
In a post-hoc analysis, the early reduction of depres-
sive symptoms measured with the IDS-C scale was
added to the linear regression models. Using the
reductions during the first 4 weeks in patients with
clinically relevant pain (> 30 mm VAS) at baseline, the
≥ 50% reduction in overall pain VAS (F = 94.5, p <
Table 1 Patient Demographics, Diagnosis, and Medical History
Variable n (%) Mean (SD)
Age (years; N = 4508) 52.2 (12.7)
Gender: Female (N = 4513) 3241 (71.8)
BMI (kg/m
2; N = 4503) 27.1 (5.1)
Living alone (N = 4261) 1113 (26.1)
Currently unable to work
a (N = 4321) 1708 (39.5)
Duration of inability to work in the last 12 months (weeks; N = 4140) 6.3 (13.1)
Diagnosis by ICD Code (reported by > 5% of patients; N = 4493)
Moderate depressive episode (F32.1) 1376 (30.6)
Recurrent depressive disorder, current episode moderate (F33.1) 1204 (26.8)
Severe depressive episode without psychotic symptoms (F32.2) 569 (12.7)
Recurrent depressive disorder, current episode severe without psychotic symptoms (F33.2) 362 (8.1)
Depressive episode, unspecified (F32.9) 347 (7.7)
Age at onset of depression (years; N = 4445) 41.5 (14.3)
Time since onset of depression (years; N = 4442) 10.6 (10.7)
Any hospitalization during the last 12 months (N = 4485) 473 (10.5)
Any suicide attempt during the last 12 months (N = 4473) 102 (2.3)
Any concomitant psychiatric diseases (N = 4501) 2032 (45.2)
Most common (> 10% of patients) concomitant psychiatric diseases:
b
Somatoform disorders 1269 (28.2)
Anxiety disorders/obsessive-compulsive disorders 661 (14.7)
Further psychiatric diseases 497 (11.0)
History of antidepressant therapy in the last week (N = 4500) yes 2678 (59.5)
Most common (> 5% of patients) antidepressant therapies:
Tricyclic antidepressant 1320 (29.3)
Selective serotonin reuptake inhibitor 1063 (23.6)
Noradrenergic and specific serotonergic antidepressant 385 (8.6)
Selective serotonin and noradrenaline reuptake inhibitor 234 (5.2)
Patients with overall pain VAS > 30 mm 3525 (80.0)
Any permanent pain medication (N = 4503) 1453 (32.3)
Any on-demand pain medication in the last 12 months (N = 4481) 2728 (60.9)
Any concomitant somatic diseases (N = 4495) 3241 (72.1)
Most common (> 10% of patients) concomitant somatic diseases:
b
Muscle and skeleton diseases 1514 (33.7)
Hypertension 1258 (28.0)
Neurologic diseases 555 (12.3)
Metabolic diseases 503 (11.2)
Gastrointestinal diseases 470 (10.5)
Allergies 467 (10.4)
BMI = Body mass index; N = Number of patients with available data; n = Number of patients in category; SD = Standard deviation.
a Answer ‘yes’ to the question ‘Is the patient unable to work today?’.
b As selected from the check list.
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IDS-C total score after 4 weeks (F = 91.8 p < 0.0001,
estimate = 11.28) showed the strongest associations
with 6-month KUSTA depressive outcomes. An analy-
sis based on the 2-week results with a 20% reduction
criterion also showed a strong association of the
reduction in overall pain VAS (F = 35.9, p < 0.0001,
estimate = 6.52) and the IDS-C total score (F = 29.4, p
< 0.0001, estimate = 5.89) with 6-month KUSTA
depression outcomes.
Safety Results
During the observation period, 132 patients (3.1%) were
hospitalized due to depression, the median duration was
23 days (range: 1 to 153 days).
At least one treatment emergent adverse event (TEAE)
was reported by 741 patients (17.2%). The most fre-
quently affected system organ classes (at least 3% of
patients with an event) were gastrointestinal disorders
(395 patients [9.2%]), psychiatric disorders (200 [4.6%]),
nervous system disorders (153 [3.5%]), and skin and
subcutaneous tissue disorders (131 [3.0%]). The only
T E A Et h a tw a sr e p o r t e db ym o r et h a n3 %o fp a t i e n t s
was nausea (226 patients [5.2%]).
Serious TEAEs were reported by a total of 34 patients
(0.79%). The only serious TEAEs reported by more than
2 patients were depression (6 patients [0.14%]) and diar-
rhea (3 [0.07%]). Serious TEAEs included one report of
suicidal ideation; however, no suicide or suicide attempt
was reported. Two patients had fatal TEAEs: renal can-
cer; cerebral hemorrhage.
At each post-baseline visit, mean weight had
decreased compared to baseline, but mean decreases
were not greater than 0.23 kg below baseline at any
time point.
Discussion
In the PADRE study, 80% of the depressed patients had
moderate to severe overall pain at baseline. For all
patients, the mean overall pain VAS score was 55.0 mm.
This high pain intensity could partly result from the fact
that depressed patients with pain syndromes could be
overrepresented in this study because of the proven
analgesic efficacy of duloxetine [14,23]. However, the
Table 2 Descriptive Statistics of Efficacy Variables (KUSTA, IDS-C, Pain VAS, SSI) Over Time
Variable Baseline
(N = 4517)
2 Weeks
(N = 4242)
4 Weeks
(N = 3991)
3 Months
(N = 3681)
6 Months
(N = 3320)
Mean KUSTA score
a, mean (SD) 25.2 (16.8) 34.4 (20.3) 43.3 (23.3) 53.1 (24.7) 58.9 (25.9)
IDS-C total score, mean (SD) 39.2 (12.4) 31.8 (13.0) 25.2 (12.8) 19.9 (12.6) 16.1 (11.9)
VAS (mm), mean (SD)
Overall pain 55.0 (26.6) 44.9 (25.5) 39.1 (25.6) 34.2 (25.4) 30.5 (25.4)
Headache 40.8 (31.7) 34.3 (29.7) 30.1 (28.2) 27.2 (27.2) 23.7 (25.6)
Back pain 50.3 (31.7) 40.8 (30.1) 35.9 (28.9) 32.9 (28.5) 29.7 (27.9)
Joint pain 48.5 (32.3) 38.8 (30.0) 34.3 (28.7) 31.4 (28.4) 28.4 (28.3)
Shoulder/neck pain 43.9 (32.8) 34.5 (29.6) 30.2 (28.4) 27.7 (28.1) 24.5 (27.0)
Chest pain 24.8 (28.7) 19.7 (25.1) 17.0 (23.1) 15.8 (22.5) 14.5 (21.5)
Abdomen pain 24.4 (28.4) 20.2 (24.8) 17.3 (23.0) 16.6 (22.8) 14.5 (20.9)
≥ 30% reduction in VAS overall pain:
All patients, n (%)
NA 1279 (31.9) 1771 (46.9) 1968 (56.2) 1949 (61.9)
Females, n (%) NA 913 (31.8) 1277 (47.2) 1419 (56.4) 1392 (61.6)
Males, n (%) NA 366 (32.1) 494 (46.0) 549 (55.6) 557 (62.6)
Patients with > 30 mm in VAS overall pain at
baseline
NA 1060 (32.8) 1492 (48.8) 1689 (59.4) 1664 (65.4)
≥ 50% reduction in VAS overall pain:
All patients, n (%)
NA 705 (17.6) 1129 (29.9) 1427 (40.7) 1516 (48.1)
Females, n (%) NA 500 (17.4) 811 (30.0) 1019 (40.5) 1075 (47.6)
Males, n (%) NA 205 (18.0) 318 (29.6) 408 (41.3) 441 (49.6)
Patients with > 30 mm in VAS overall pain at
baseline
NA 539 (16.7) 910 (29.8) 1193 (42.0) 1273 (50.1)
SSI, mean (SD)
Total score 2.47 (0.69) 2.20 (0.68) 2.00 (0.66) 1.84 (0.66) 1.72 (0.65)
Painful symptoms 2.76 (0.88) 2.43 (0.84) 2.23 (0.81) 2.04 (0.79) 1.90 (0.77)
Non-painful symptoms 2.38 (0.69) 2.13 (0.67) 1.92 (0.65) 1.77 (0.66) 1.65 (0.64)
KUSTA = Kurz-Skala Stimmung/Aktivierung; N = Total number of available patients (number of patients with available data varied depending on variable and
visit); SD = Standard deviation. NA = Not applicable; SD = Standard deviation; SSI = Somatic Symptom Inventory; VAS = Visual analogue scales.
a Mean of KUSTA scores items mood, activity, tension/relaxation and sleep,, range: score 0-100
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PADRE study is in line with the literature reporting pre-
valence rates of 56% [33], 65% [1] and 88% [34].
For 72.1% of the PADRE population, concomitant
somatic diseases were documented most frequently
‘muscle and skeleton diseases’ (33.7%). The high preva-
lence of patients suffering from pain conditions may
raise concern that common depression rating scales
overestimate depressive symptoms in these patients, as
they may score higher on somatic items because of their
pain rather than because of their mood. However, Poole
et al. [35] showed a good correlation of a commonly
used depression rating scale that includes somatic items
(Beck Depression Inventory-II) with a structured clinical
interview for DSM-IV Axis Disorders (SCID) which
represents a gold standard for assessment of depressive
symptomatology.
The main finding of our study is that early change in
pain severity was strongly associated with a long-term
reduction of depressive symptoms according to the
mean KUSTA score. Pain responders also had a higher
chance of achieving a 50% reduction in the IDS-C total
score after 6 months.
This association of an early improvement in pain with
long term depression outcomes was already seen after 2
weeks, albeit, to a smaller extent than after 4 weeks.
This is remarkable, considering that 72.9% of the
patients started duloxetine treatment with a dose of 30
mg/day, which is lower than the recommended starting
and maintenance dose.
Patients with a VAS pain reduction of ≥ 50% after 2
and 4 weeks, showed also higher remission rates after 6
months than patients without a ≥ 50% pain reduction
(Figure 2).
For clinicians, it is of interest whether or not early
improvement of pain is a better predictor of the long-
term outcome to antidepressant treatment than early
improvement of depressive symptoms. Therefore, post-
hoc analyses were performed including early response in
depressive symptoms after 2 and 4 weeks (as measured
with IDS-C total score). Results showed that an early
pain response had similar predictive value compared to
early depression response for long term depressive out-
comes as measured with the KUSTA scale.
T h em a i nr e s u l t so ft h eP A D R Es t u d ya r ei nc o n t r a s t
to a recent publication [36], reporting a very low
Table 3 Statistically Significant Variables at Baseline and after 4 Weeks in the Regression Analysis of the Mean KUSTA
Score at 6 Months
a) All patients (N = 2574)
Variable F-value p-value Estimate
a
≥ 50% reduction in overall pain VAS during the first 4 weeks 158.6 < 0.0001 13.32
Number of weeks unable to work in the last 12 months 40.9 < 0.0001 -0.23
Overall pain VAS at baseline (per 20 mm) 33.9 < 0.0001 -2.34
Any concomitant somatic disease at baseline 30.5 < 0.0001 -5.86
SSI non-painful symptoms subscore at baseline 18.0 < 0.0001 -3.49
Living alone 13.8 < 0.001 -3.89
≥ 50% reduction in the SSI painful symptoms subscore during the first 4 weeks 11.0 < 0.001 6.22
Any baseline psychotropic medication 7.9 0.005 -2.93
Duration of depression (years) 6.1 0.014 -0.12
Mean KUSTA at baseline (per 20 mm) 5.6 0.018 1.47
b) Patients with baseline pain VAS > 30 mm (N = 2053)
Variable F-value p-value Estimate
a
≥ 50% reduction in overall pain VAS during the first 4 weeks 151.4 < 0.0001 14.74
Number of weeks unable to work in the last 12 months 40.2 < 0.0001 -0.25
Any concomitant somatic disease at baseline 22.1 < 0.0001 -5.98
SSI non-painful symptoms subscore at baseline 16.0 < 0.0001 -3.54
Overall pain VAS at baseline (per 20 mm) 15.0 < 0.001 -2.50
Living alone 13.3 < 0.001 -4.24
Mean KUSTA at baseline (per 20 mm) 9.9 0.002 2.36
≥ 50% reduction in the SSI painful symptoms subscore during the first 4 weeks 8.7 0.003 5.84
Age 4.1 0.044 -0.09
Duration of Depression (years) 3.9 0.048 -0.10
a For binary outcomes (yes/no) the given estimate reflects the average impact on the KUSTA score if the respective factor is present ("yes”) compared to the
situation where it is not present ("no”), e.g. in this model the mean KUSTA score for a patient living alone is estimated to be 3.89 points lower than for patient
not living alone. For continuous outcomes, the estimate reflects the difference in the KUSTA score for each unit increase of the respective covariate, e.g. in this
model for each additional year of duration of depression the mean KUSTA score is reduced by 0.12 points.
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sant responses in six placebo-controlled trials assessing
the efficacy of duloxetine in patients with major depres-
sive disorder. However, the studies used in these post-
hoc meta-analyses were not designed to assess the rela-
tionship between antidepressant and analgesic response,
and there were only few data points available for early
response assessment.
Other studies support the association between early
improvement in pain and long-term antidepressant
response [15,37]. Pooled data from two 9-week rando-
mized, double-blind duloxetine studies showed that the
remission rate for pain responders (improvement in
VAS overall pain from baseline to last observation ≥
50%) was twice that observed for pain non-responders
(36.2% vs. 17.8%, p < 0.001). Improvements in pain
severity were also related to improved quality of life and
improved clinician- and patient-rated global health out-
comes [14]. A secondary analysis of a 12-week open-
label trial with duloxetine in 249 patients [25] found
similar results. Patients who experienced clinically
important pain reduction in the first week of duloxetine
treatment were significantly more likely to reach remis-
sion at endpoint than the patients without this pain
reduction (64.0% vs. 35.6%, p < 0.001).
The results of the PADRE study are of interest in the
context of other recent research [27,38-42]. Evidence was
provided questioning the belief that antidepressant
response usually appears with a delay of several weeks,
and new evidence continues to accumulate that indivi-
dual improvement within the first 2 weeks is a key pre-
dictor of treatment response. Lack of early response in
depression symptom subscales was highly predictive of a
lack of sustained remission [41]. A lack of improvement
during the first 2 weeks of therapy may indicate that
changes in depression management should be considered
earlier than conventionally thought [32]. Results from
PADRE also suggest that early improvements in conco-
mitant PPS measured with simple VAS scales should be
considered in treatment decisions during the initial 2-4
weeks of a new antidepressive treatment. The results of
PADRE could also be important for patients with gener-
alized anxiety disorder with or without comorbid MDD,
as the clinical relevance of PPS and resulting functional
impairment has been reported [43,44].
As this was a large observational study in daily clinical
practice, several methodological limitations such as the
absence of monitoring or a high number of patients lost
to follow-up were unavoidable and may lead to concerns
with regard to data quality. However, this non-interven-
tional approach reflects current treatment of patients
with MDD by office-based psychiatrists and should
therefore allow generalization of our results to clinical
practice. Perhaps the most serious shortcoming of non-
interventional trials is selection bias because of absence
of randomization. Another limitation of the study is the
lack of a control group, as only duloxetine-treated
patients were included.
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Figure 2 Remission Rates (IDS-C ≤ 12) after 6 Months of Treatment with Duloxetine.
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Page 8 of 10Conclusions
Pain is a frequent and often severe concomitant symp-
tom in depressive patients in clinical practice. Pain
reduction after 2 and 4 weeks can be used to estimate
long-term outcomes regarding successful antidepressive
treatment with duloxetine.
The present results emphasize the importance of PPS
associated with depression because of their potential
role in predicting and achieving depressive symptom
remission.
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